Klaus Uberla
Erlangen, BY 91058, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications
Structure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
Journal: Journal of medicinal chemistry
Published: July 16, 2026
Silica-coated papillomavirus-based nanoparticles: a shielded scaffold for HIV-1 vaccines.
Journal: Biomaterials science
Published: May 07, 2026
In danger: HIV vaccine research and development in Europe.
Journal: PLOS global public health
Published: April 08, 2025
DNAm landscape up to 4 months post SARS-CoV-2 infection: insights from four population-based cohorts.
Journal: Clinical epigenetics
Published: April 02, 2025
Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection.
Journal: PLoS pathogens
Published: September 27, 2024
Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model.
Journal: Journal of virology
Published: June 20, 2024
Two Sides of the Same Coin-Mechanistic Insight, Diagnostic Application and Therapeutic Translation of Bacterial and Host-Derived Extracellular Vesicles.
Journal: Journal of extracellular biology
Published: June 05, 2024
Chronic inflammation degrades CD4 T cell immunity to prior vaccines in treated HIV infection.
Journal: Nature communications
Published: April 25, 2024
Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2.
Journal: Journal of medical virology
Published: January 09, 2024
Oriented display of HIV-1 Env trimers by a novel coupling strategy enhances B cell activation and phagocytosis.
Journal: Frontiers in immunology
Published: November 25, 2023
Last Updated: 09/26/2026